These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
75 related articles for article (PubMed ID: 8768271)
41. Lovastatin. Feeman WE Am Fam Physician; 1988 Aug; 38(2):65-7. PubMed ID: 3407588 [No Abstract] [Full Text] [Related]
42. [Problem-oriented laboratory findings of lipid parameters]. Blazej V; Dusková S; Hudcová M Cas Lek Cesk; 1982 Oct; 121(41):1266-9. PubMed ID: 6897373 [No Abstract] [Full Text] [Related]
43. Treatment of and screening for hyperlipidemia. Barth JD N Engl J Med; 1993 Oct; 329(15):1125; author reply 1127. PubMed ID: 8371741 [No Abstract] [Full Text] [Related]
44. A "hot" topic in dyslipidemia management--"how to beat a flush": optimizing niacin tolerability to promote long-term treatment adherence and coronary disease prevention. Jacobson TA Mayo Clin Proc; 2010 Apr; 85(4):365-79. PubMed ID: 20360295 [TBL] [Abstract][Full Text] [Related]
45. Lipid-lowering effect of simvastatin in patients of type 2 diabetes mellitus. Udawat H; Goyal RK Indian Heart J; 2001; 53(2):172-6. PubMed ID: 11428472 [TBL] [Abstract][Full Text] [Related]
46. Apolipoprotein modifying effects of statins and fibrate in various age groups of coronary artery disease patients. Sharma R; Mahajan M; Singh B; Bal BS; Kant R J Indian Med Assoc; 2006 Sep; 104(9):492-4, 496, 498. PubMed ID: 17388006 [TBL] [Abstract][Full Text] [Related]
47. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice. Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658 [TBL] [Abstract][Full Text] [Related]
48. [Use of hydroxymethylglutaryl coenzyme A reductase inhibitors in patients with post-transplantation hyperlipemia]. Martínez-Castelao A Med Clin (Barc); 1995 Nov; 105(18):719. PubMed ID: 8538262 [No Abstract] [Full Text] [Related]
49. Treatment of lipids. Implications for the general practitioner. Simons LA Aust Fam Physician; 1996 Jul; 25(7):1053-9. PubMed ID: 8768271 [TBL] [Abstract][Full Text] [Related]
50. Pharmacologic treatment of type 2 diabetic dyslipidemia. Moon YS; Kashyap ML Pharmacotherapy; 2004 Dec; 24(12):1692-713. PubMed ID: 15585439 [TBL] [Abstract][Full Text] [Related]
51. Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid--a position paper developed by the European Consensus Panel on HDL-C. Chapman MJ; Assmann G; Fruchart JC; Shepherd J; Sirtori C; Curr Med Res Opin; 2004 Aug; 20(8):1253-68. PubMed ID: 15324528 [TBL] [Abstract][Full Text] [Related]
52. Niacin-based therapy for dyslipidemia: past evidence and future advances. Ito MK Am J Manag Care; 2002 Sep; 8(12 Suppl):S315-22. PubMed ID: 12240703 [TBL] [Abstract][Full Text] [Related]